Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.
Yildiz I, Bilici A, Karadurmuş N, Ozer L, Tural D, Kaplan MA, Akman T, Bayoglu IV, Uysal M, Yildiz Y, Tanriverdi Ö, Yazici O, Sürmeli Z, Serdar Turhal N, Bavbek S, Selçukbiricik F, Koca D, Basaran M. Yildiz I, et al. Among authors: karadurmus n. Tumori. 2018 Dec;104(6):444-450. doi: 10.5301/tj.5000635. Epub 2018 May 9. Tumori. 2018. PMID: 28731496
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: karadurmus n. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778
The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer.
Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Bilgin B, Taban H, Kucukarda A, Erturk I, Hızal M, Yıldız B, Yıldırım N, Demirci U, Sendur MA, Utkan G, Kılıckap S, Cicin I, Karadurmus N, Ürün Y. Yasar HA, et al. Among authors: karadurmus n. J Oncol Pharm Pract. 2020 Jul;26(5):1110-1116. doi: 10.1177/1078155219883004. Epub 2019 Oct 25. J Oncol Pharm Pract. 2020. PMID: 31653193
Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study).
Hizal M, Sendur MA, Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S, Taban H, Kucukarda A, Erturk I, Bilgin B, Yıldırım N, Demirci U, Kılıckap S, Cicin I, Karadurmus N, Yalcin B, Ürün Y. Hizal M, et al. Among authors: karadurmus n. J Oncol Pharm Pract. 2020 Oct;26(7):1583-1589. doi: 10.1177/1078155219900908. Epub 2020 Feb 13. J Oncol Pharm Pract. 2020. PMID: 32054412
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.
Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I, Gumusay O, Bilici A, Akdeniz N, Bahceci A, Demir H, Esin E, Üyeturk U, Nihat Okten I, Erturk I, Turk HM, Topaloglu US, Basoglu T, Serdar Turhal N, Yesil Cinkir H, Menekse S, Cakmak Y, Urun Y, Acar R, Kut E, Dal P, Sakalar T, Halit Aktepe O, Karadurmus N, Bilici A. Yildiz B, et al. Among authors: karadurmus n. J BUON. 2020 Mar-Apr;25(2):1130-1135. J BUON. 2020. PMID: 32521916 Free article.
Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation.
Erturk I, Karadurmus N, Kızıloz H, Acar R, Yildiz B, Aykan MB, Esen R, Buyukturan G, Urun Y, Erdem G, Arpacı F. Erturk I, et al. Among authors: karadurmus n. J Oncol Pharm Pract. 2021 Oct;27(7):1657-1664. doi: 10.1177/1078155220964540. Epub 2020 Oct 13. J Oncol Pharm Pract. 2021. PMID: 33050802
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Clinical presentation and course of the novel coronavirus disease 2019 in patients with various types of cancer: A retrospective case-control analysis of an experienced cancer center in Turkey.
Acar R, Yilmaz G, Savasci U, Aykan MB, Kiziloz H, Cuce F, Kadioglu E, Filiz M, Fidan G, Eksert S, Taskin G, Dogan D, Arslan Y, Tasci C, Kayahan N, Dogan T, Basgoz BB, Sertoglu E, Erturk I, Keskin GSY, Okcelik S, Yildiz B, Karadurmus N. Acar R, et al. Among authors: karadurmus n. J Cancer Res Ther. 2021 Apr-Jun;17(2):556-564. doi: 10.4103/jcrt.JCRT_715_20. J Cancer Res Ther. 2021. PMID: 34121708 Free article.
111 results